Harbour BioMed Enters into a Collaboration with Insilico Medicine to Advance AI-Driven Antibody Discovery and Development
Shots:
- Harbour BioMed has entered into a strategic collaboration with Insilico Medicine to accelerate therapeutic antibody development, combining their expertise in antibody discovery and artificial intelligence
- The companies will also collaborate on early-stage drug discovery targeting novel antibodies, leveraging Insilico's AI expertise and Harbour BioMed's wet lab capabilities for immunology, oncology, and neuroscience, aiming to address unmet medical needs
- Since 2021, the company has built a pipeline of 30 assets using its Pharma.AI platform, with 10 receiving IND clearance, setting a benchmark for AI-driven drug discovery. In July 2024, Insilico launched Generative Biologics, an AI tool for de novo protein engineering to speed up biologics development
Ref: Harbour BioMed | Image: Harbour BioMed & Insilico Medicine
Related News:- Harbour BioMed Receives the US FDA’s IND Clearance to Initiate P-I Study of HBM9027 for Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
